Kennon Heard
Concepts (647)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Acetaminophen | 40 | 2025 | 261 | 8.430 |
Why?
| | Chemical and Drug Induced Liver Injury | 15 | 2023 | 135 | 4.660 |
Why?
| | Analgesics, Non-Narcotic | 21 | 2025 | 124 | 4.510 |
Why?
| | Drug Overdose | 31 | 2025 | 346 | 4.110 |
Why?
| | Poison Control Centers | 13 | 2025 | 78 | 3.480 |
Why?
| | Emergency Service, Hospital | 41 | 2023 | 2114 | 3.300 |
Why?
| | Poisoning | 17 | 2017 | 119 | 2.930 |
Why?
| | Alanine Transaminase | 14 | 2023 | 147 | 2.560 |
Why?
| | Acetylcysteine | 11 | 2023 | 142 | 2.550 |
Why?
| | Cocaine | 10 | 2011 | 173 | 2.370 |
Why?
| | Cannabis | 9 | 2020 | 500 | 2.280 |
Why?
| | Prescription Drugs | 9 | 2018 | 112 | 2.190 |
Why?
| | Antidotes | 9 | 2020 | 140 | 1.490 |
Why?
| | Analgesics, Opioid | 8 | 2023 | 1092 | 1.470 |
Why?
| | Legislation, Drug | 5 | 2017 | 83 | 1.450 |
Why?
| | Cysteine | 4 | 2017 | 204 | 1.340 |
Why?
| | Antipsychotic Agents | 7 | 2019 | 209 | 1.290 |
Why?
| | Marijuana Use | 4 | 2021 | 206 | 1.180 |
Why?
| | Medication Errors | 5 | 2015 | 97 | 1.140 |
Why?
| | Male | 103 | 2022 | 68250 | 1.100 |
Why?
| | Emergency Medicine | 6 | 2019 | 241 | 1.080 |
Why?
| | Pain | 9 | 2020 | 779 | 1.070 |
Why?
| | Humans | 155 | 2025 | 138972 | 1.060 |
Why?
| | Cocaine-Related Disorders | 5 | 2011 | 135 | 1.050 |
Why?
| | Drug Packaging | 2 | 2017 | 43 | 1.040 |
Why?
| | Toxicology | 4 | 2021 | 44 | 1.040 |
Why?
| | Female | 95 | 2022 | 74016 | 0.950 |
Why?
| | Medication Reconciliation | 2 | 2016 | 30 | 0.940 |
Why?
| | Adult | 73 | 2022 | 38393 | 0.940 |
Why?
| | Dose-Response Relationship, Drug | 16 | 2017 | 2047 | 0.920 |
Why?
| | Spider Bites | 5 | 2019 | 7 | 0.870 |
Why?
| | Antidepressive Agents, Tricyclic | 5 | 2014 | 31 | 0.870 |
Why?
| | Antivenins | 5 | 2019 | 28 | 0.870 |
Why?
| | Diphenhydramine | 4 | 2023 | 36 | 0.860 |
Why?
| | Akathisia, Drug-Induced | 2 | 2020 | 6 | 0.850 |
Why?
| | Thiazoles | 4 | 2009 | 127 | 0.830 |
Why?
| | Prescription Drug Monitoring Programs | 1 | 2023 | 14 | 0.810 |
Why?
| | Spider Venoms | 4 | 2019 | 9 | 0.810 |
Why?
| | Benzodiazepines | 6 | 2023 | 154 | 0.810 |
Why?
| | Muscarinic Antagonists | 3 | 2023 | 30 | 0.780 |
Why?
| | Lorazepam | 3 | 2023 | 25 | 0.770 |
Why?
| | Heart Arrest | 8 | 2018 | 383 | 0.760 |
Why?
| | Young Adult | 30 | 2020 | 13371 | 0.760 |
Why?
| | Middle Aged | 54 | 2022 | 33782 | 0.750 |
Why?
| | Seizures | 6 | 2011 | 431 | 0.730 |
Why?
| | Referral and Consultation | 2 | 2020 | 795 | 0.730 |
Why?
| | Physostigmine | 2 | 2020 | 13 | 0.720 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 2 | 2019 | 358 | 0.720 |
Why?
| | Decision Support Systems, Clinical | 2 | 2023 | 242 | 0.720 |
Why?
| | Emergency Treatment | 4 | 2015 | 124 | 0.720 |
Why?
| | Piperazines | 4 | 2009 | 345 | 0.720 |
Why?
| | Black Widow Spider | 4 | 2019 | 7 | 0.710 |
Why?
| | Medical History Taking | 3 | 2018 | 117 | 0.710 |
Why?
| | Dopamine Uptake Inhibitors | 3 | 2011 | 60 | 0.700 |
Why?
| | Delirium | 2 | 2020 | 97 | 0.690 |
Why?
| | Anti-Arrhythmia Agents | 4 | 2014 | 111 | 0.670 |
Why?
| | Abdominal Pain | 2 | 2019 | 142 | 0.670 |
Why?
| | Suicide, Attempted | 5 | 2012 | 385 | 0.650 |
Why?
| | Hospitals, Pediatric | 4 | 2018 | 516 | 0.640 |
Why?
| | Back Pain | 1 | 2020 | 52 | 0.640 |
Why?
| | Vasoconstrictor Agents | 4 | 2009 | 133 | 0.640 |
Why?
| | Free Radical Scavengers | 2 | 2011 | 87 | 0.630 |
Why?
| | Buprenorphine | 2 | 2020 | 174 | 0.620 |
Why?
| | Retrospective Studies | 31 | 2023 | 15901 | 0.620 |
Why?
| | Patient Handoff | 1 | 2020 | 38 | 0.620 |
Why?
| | Emergency Medical Services | 5 | 2025 | 635 | 0.610 |
Why?
| | Haloperidol | 1 | 2019 | 33 | 0.610 |
Why?
| | Ketorolac | 1 | 2019 | 25 | 0.610 |
Why?
| | Social Work | 1 | 2020 | 85 | 0.590 |
Why?
| | Pharmacoepidemiology | 1 | 2018 | 21 | 0.590 |
Why?
| | Gastric Lavage | 3 | 2009 | 9 | 0.570 |
Why?
| | Tertiary Care Centers | 3 | 2017 | 169 | 0.570 |
Why?
| | Immunoglobulin Fab Fragments | 4 | 2019 | 59 | 0.570 |
Why?
| | Colorado | 15 | 2021 | 4543 | 0.560 |
Why?
| | Vomiting | 6 | 2019 | 129 | 0.560 |
Why?
| | Hypotension | 2 | 2022 | 120 | 0.550 |
Why?
| | Prospective Studies | 18 | 2023 | 7661 | 0.550 |
Why?
| | Substance-Related Disorders | 5 | 2012 | 1085 | 0.550 |
Why?
| | Drug Storage | 2 | 2017 | 53 | 0.540 |
Why?
| | Child | 28 | 2023 | 21936 | 0.540 |
Why?
| | Accidents, Home | 1 | 2017 | 33 | 0.530 |
Why?
| | Cannabinoids | 3 | 2017 | 168 | 0.520 |
Why?
| | Medical Marijuana | 2 | 2019 | 123 | 0.520 |
Why?
| | Electronic Health Records | 4 | 2024 | 1090 | 0.520 |
Why?
| | Plant Preparations | 2 | 2015 | 38 | 0.520 |
Why?
| | Fibrin Fibrinogen Degradation Products | 2 | 2007 | 91 | 0.520 |
Why?
| | Calcium Gluconate | 1 | 2016 | 3 | 0.510 |
Why?
| | Pulmonary Embolism | 3 | 2021 | 234 | 0.510 |
Why?
| | Quaternary Ammonium Compounds | 1 | 2016 | 51 | 0.500 |
Why?
| | Hypocalcemia | 1 | 2016 | 31 | 0.500 |
Why?
| | Health Records, Personal | 1 | 2016 | 28 | 0.490 |
Why?
| | Nonprescription Drugs | 4 | 2016 | 64 | 0.490 |
Why?
| | Mobile Applications | 1 | 2018 | 178 | 0.480 |
Why?
| | Blood Proteins | 1 | 2017 | 244 | 0.480 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 5 | 2023 | 253 | 0.470 |
Why?
| | Fat Emulsions, Intravenous | 2 | 2014 | 29 | 0.470 |
Why?
| | Antidepressive Agents | 2 | 2012 | 245 | 0.470 |
Why?
| | Practice Patterns, Physicians' | 3 | 2023 | 1321 | 0.470 |
Why?
| | Liver | 6 | 2022 | 1807 | 0.460 |
Why?
| | Prescription Drug Misuse | 1 | 2015 | 47 | 0.460 |
Why?
| | Electrocardiography | 5 | 2013 | 610 | 0.450 |
Why?
| | Treatment Outcome | 18 | 2020 | 10921 | 0.450 |
Why?
| | Child, Preschool | 13 | 2018 | 11158 | 0.430 |
Why?
| | Infant | 12 | 2018 | 9577 | 0.430 |
Why?
| | Asymptomatic Diseases | 2 | 2013 | 90 | 0.430 |
Why?
| | Crime | 2 | 2011 | 60 | 0.420 |
Why?
| | Observer Variation | 3 | 2010 | 350 | 0.420 |
Why?
| | Energy Drinks | 1 | 2013 | 2 | 0.410 |
Why?
| | Adrenergic alpha-2 Receptor Agonists | 1 | 2013 | 24 | 0.410 |
Why?
| | Performance-Enhancing Substances | 1 | 2013 | 10 | 0.410 |
Why?
| | Arrhythmias, Cardiac | 3 | 2022 | 328 | 0.400 |
Why?
| | Accidents | 1 | 2013 | 40 | 0.400 |
Why?
| | Bradycardia | 1 | 2013 | 52 | 0.400 |
Why?
| | Adolescent | 27 | 2020 | 21581 | 0.400 |
Why?
| | Poisons | 2 | 2023 | 20 | 0.400 |
Why?
| | Double-Blind Method | 7 | 2020 | 1949 | 0.400 |
Why?
| | Plasmapheresis | 1 | 2013 | 24 | 0.400 |
Why?
| | Diet Surveys | 1 | 2013 | 95 | 0.400 |
Why?
| | Amphotericin B | 1 | 2013 | 34 | 0.390 |
Why?
| | Hematemesis | 1 | 2012 | 3 | 0.390 |
Why?
| | Aspartate Aminotransferases | 3 | 2010 | 83 | 0.390 |
Why?
| | beta-Alanine | 1 | 2012 | 17 | 0.390 |
Why?
| | Foreign Bodies | 2 | 2011 | 106 | 0.390 |
Why?
| | Stomach Diseases | 1 | 2012 | 19 | 0.390 |
Why?
| | Phytotherapy | 1 | 2013 | 85 | 0.390 |
Why?
| | Ethers | 1 | 2012 | 19 | 0.390 |
Why?
| | Sulfonylurea Compounds | 2 | 2010 | 48 | 0.380 |
Why?
| | Citalopram | 1 | 2012 | 35 | 0.380 |
Why?
| | Liver Function Tests | 7 | 2020 | 105 | 0.380 |
Why?
| | Antithrombins | 1 | 2012 | 62 | 0.380 |
Why?
| | Drug Administration Schedule | 5 | 2014 | 769 | 0.370 |
Why?
| | Antifungal Agents | 1 | 2013 | 140 | 0.370 |
Why?
| | Propafenone | 1 | 2011 | 2 | 0.370 |
Why?
| | Genetic Predisposition to Disease | 1 | 2020 | 2362 | 0.370 |
Why?
| | Thiophenes | 1 | 2012 | 122 | 0.370 |
Why?
| | C-Peptide | 2 | 2010 | 163 | 0.360 |
Why?
| | Aged | 27 | 2019 | 24172 | 0.360 |
Why?
| | Firesetting Behavior | 1 | 2011 | 1 | 0.360 |
Why?
| | Disease Models, Animal | 9 | 2011 | 4316 | 0.360 |
Why?
| | Anaphylaxis | 2 | 2012 | 107 | 0.360 |
Why?
| | Dronabinol | 4 | 2021 | 238 | 0.360 |
Why?
| | Infusions, Intravenous | 6 | 2013 | 411 | 0.360 |
Why?
| | Alcohol Drinking | 4 | 2012 | 816 | 0.360 |
Why?
| | Clinical Enzyme Tests | 2 | 2013 | 10 | 0.360 |
Why?
| | Charcoal | 4 | 2006 | 26 | 0.360 |
Why?
| | Benzimidazoles | 1 | 2012 | 177 | 0.350 |
Why?
| | Temperance | 2 | 2010 | 20 | 0.350 |
Why?
| | Opioid-Related Disorders | 2 | 2020 | 546 | 0.350 |
Why?
| | Administration, Intravenous | 4 | 2016 | 156 | 0.350 |
Why?
| | Chemical and Drug Induced Liver Injury, Chronic | 1 | 2011 | 11 | 0.350 |
Why?
| | Cholinergic Antagonists | 1 | 2011 | 24 | 0.340 |
Why?
| | Brain Edema | 1 | 2011 | 64 | 0.340 |
Why?
| | Amitriptyline | 2 | 2001 | 22 | 0.340 |
Why?
| | Evidence-Based Medicine | 4 | 2023 | 743 | 0.340 |
Why?
| | Aged, 80 and over | 15 | 2018 | 7685 | 0.340 |
Why?
| | Reproducibility of Results | 6 | 2024 | 3313 | 0.340 |
Why?
| | Blood Chemical Analysis | 3 | 2021 | 110 | 0.340 |
Why?
| | Burns | 2 | 2015 | 340 | 0.340 |
Why?
| | Self-Injurious Behavior | 1 | 2012 | 136 | 0.340 |
Why?
| | Immunologic Factors | 2 | 2019 | 243 | 0.330 |
Why?
| | Tachycardia, Ventricular | 1 | 2012 | 172 | 0.330 |
Why?
| | Liver Failure | 1 | 2011 | 80 | 0.330 |
Why?
| | Hydrofluoric Acid | 2 | 2016 | 6 | 0.330 |
Why?
| | Pharmaceutical Vehicles | 1 | 2010 | 12 | 0.330 |
Why?
| | Propylene Glycol | 1 | 2010 | 9 | 0.320 |
Why?
| | Time Factors | 12 | 2020 | 6869 | 0.320 |
Why?
| | Barium | 1 | 2009 | 26 | 0.320 |
Why?
| | Population Surveillance | 1 | 2013 | 482 | 0.320 |
Why?
| | Explosive Agents | 1 | 2009 | 7 | 0.320 |
Why?
| | United States | 18 | 2025 | 15074 | 0.320 |
Why?
| | Hypokalemia | 1 | 2009 | 24 | 0.320 |
Why?
| | Imines | 2 | 2022 | 8 | 0.320 |
Why?
| | Liver Diseases, Alcoholic | 2 | 2007 | 91 | 0.310 |
Why?
| | Warfarin | 1 | 2010 | 153 | 0.310 |
Why?
| | Acidosis, Lactic | 1 | 2010 | 46 | 0.310 |
Why?
| | Emetics | 2 | 2006 | 7 | 0.310 |
Why?
| | Iatrogenic Disease | 1 | 2010 | 69 | 0.310 |
Why?
| | Deception | 1 | 2009 | 20 | 0.310 |
Why?
| | Random Allocation | 3 | 2007 | 362 | 0.310 |
Why?
| | Cross-Sectional Studies | 9 | 2020 | 5530 | 0.300 |
Why?
| | Benzoquinones | 2 | 2022 | 48 | 0.300 |
Why?
| | Surveys and Questionnaires | 4 | 2018 | 5884 | 0.300 |
Why?
| | Risk Assessment | 8 | 2017 | 3466 | 0.300 |
Why?
| | Risk Factors | 9 | 2017 | 10385 | 0.300 |
Why?
| | Fluorides | 2 | 2016 | 49 | 0.290 |
Why?
| | Odds Ratio | 7 | 2017 | 1084 | 0.290 |
Why?
| | Oximetry | 1 | 2009 | 118 | 0.290 |
Why?
| | Hypothermia, Induced | 1 | 2009 | 90 | 0.290 |
Why?
| | Length of Stay | 3 | 2020 | 1237 | 0.290 |
Why?
| | Cyanoacrylates | 1 | 2008 | 4 | 0.280 |
Why?
| | Eyelashes | 1 | 2008 | 4 | 0.280 |
Why?
| | Adhesives | 1 | 2008 | 13 | 0.280 |
Why?
| | Reference Values | 4 | 2017 | 801 | 0.280 |
Why?
| | Detergents | 1 | 2008 | 45 | 0.280 |
Why?
| | Intellectual Disability | 1 | 2009 | 168 | 0.280 |
Why?
| | Point-of-Care Systems | 1 | 2010 | 184 | 0.280 |
Why?
| | Hypoglycemia | 2 | 2010 | 460 | 0.280 |
Why?
| | Cardiovascular System | 1 | 2009 | 136 | 0.270 |
Why?
| | Animals | 22 | 2019 | 37243 | 0.270 |
Why?
| | Alcoholism | 4 | 2023 | 818 | 0.270 |
Why?
| | Publishing | 1 | 2009 | 145 | 0.270 |
Why?
| | Brugada Syndrome | 1 | 2007 | 14 | 0.270 |
Why?
| | Polyethylene Glycols | 1 | 2012 | 631 | 0.270 |
Why?
| | Diazepam | 1 | 2007 | 35 | 0.270 |
Why?
| | Niacin | 1 | 2007 | 17 | 0.270 |
Why?
| | Clinical Laboratory Techniques | 1 | 2008 | 95 | 0.270 |
Why?
| | Mice, Inbred Strains | 4 | 2009 | 411 | 0.260 |
Why?
| | Vitamin B Complex | 1 | 2007 | 41 | 0.260 |
Why?
| | Pediatrics | 1 | 2015 | 1079 | 0.260 |
Why?
| | Thromboembolism | 1 | 2007 | 117 | 0.250 |
Why?
| | Brain Infarction | 1 | 2006 | 23 | 0.250 |
Why?
| | Specimen Handling | 1 | 2008 | 182 | 0.250 |
Why?
| | Hypoxia-Ischemia, Brain | 1 | 2006 | 39 | 0.240 |
Why?
| | Nausea | 4 | 2014 | 111 | 0.240 |
Why?
| | Analgesics | 4 | 2017 | 225 | 0.240 |
Why?
| | Decontamination | 1 | 2006 | 31 | 0.240 |
Why?
| | Amiodarone | 1 | 2005 | 27 | 0.240 |
Why?
| | Self Report | 4 | 2021 | 842 | 0.240 |
Why?
| | Anticoagulants | 1 | 2010 | 667 | 0.240 |
Why?
| | Intention | 1 | 2007 | 175 | 0.240 |
Why?
| | Age Factors | 7 | 2017 | 3276 | 0.240 |
Why?
| | Epilepsy | 2 | 2020 | 335 | 0.240 |
Why?
| | Vasospasm, Intracranial | 1 | 2005 | 18 | 0.230 |
Why?
| | Venous Thrombosis | 1 | 2007 | 190 | 0.230 |
Why?
| | Eating | 4 | 2017 | 394 | 0.230 |
Why?
| | Randomized Controlled Trials as Topic | 5 | 2012 | 1522 | 0.230 |
Why?
| | Sodium Nitrite | 1 | 2005 | 39 | 0.230 |
Why?
| | Drug Utilization | 5 | 2014 | 169 | 0.230 |
Why?
| | Calcium | 3 | 2016 | 1188 | 0.230 |
Why?
| | Diagnostic Imaging | 1 | 2007 | 320 | 0.230 |
Why?
| | Education, Medical | 2 | 2021 | 267 | 0.220 |
Why?
| | Subarachnoid Hemorrhage | 1 | 2005 | 68 | 0.220 |
Why?
| | Databases, Factual | 1 | 2010 | 1409 | 0.220 |
Why?
| | Acute Kidney Injury | 1 | 2012 | 812 | 0.220 |
Why?
| | Coma | 2 | 2006 | 35 | 0.220 |
Why?
| | Biomarkers | 7 | 2021 | 4095 | 0.220 |
Why?
| | Hospitals, Urban | 5 | 2021 | 138 | 0.210 |
Why?
| | Injections, Intraperitoneal | 4 | 2009 | 114 | 0.210 |
Why?
| | Triage | 2 | 2025 | 241 | 0.210 |
Why?
| | Anti-Anxiety Agents | 2 | 2020 | 43 | 0.200 |
Why?
| | Case-Control Studies | 4 | 2022 | 3574 | 0.200 |
Why?
| | Animal Experimentation | 1 | 2003 | 9 | 0.200 |
Why?
| | Hypoglycemic Agents | 2 | 2010 | 1343 | 0.200 |
Why?
| | Insulin | 3 | 2019 | 2447 | 0.200 |
Why?
| | Sensitivity and Specificity | 5 | 2010 | 1939 | 0.200 |
Why?
| | Glasgow Coma Scale | 1 | 2004 | 200 | 0.200 |
Why?
| | Calcium Chloride | 1 | 2003 | 11 | 0.200 |
Why?
| | Fibrinolytic Agents | 2 | 2021 | 280 | 0.200 |
Why?
| | Hospitals, Teaching | 3 | 2014 | 115 | 0.200 |
Why?
| | Magnesium Sulfate | 1 | 2003 | 19 | 0.200 |
Why?
| | Umbilical Cord | 2 | 2021 | 86 | 0.190 |
Why?
| | Placebos | 2 | 2014 | 197 | 0.190 |
Why?
| | Documentation | 1 | 2024 | 199 | 0.190 |
Why?
| | Desipramine | 1 | 2001 | 11 | 0.180 |
Why?
| | Longevity | 3 | 2009 | 174 | 0.180 |
Why?
| | Phenylurea Compounds | 1 | 2022 | 95 | 0.180 |
Why?
| | Logistic Models | 3 | 2017 | 2093 | 0.180 |
Why?
| | Confidence Intervals | 4 | 2010 | 335 | 0.180 |
Why?
| | Severity of Illness Index | 1 | 2009 | 2849 | 0.180 |
Why?
| | Cardiopulmonary Resuscitation | 3 | 2018 | 324 | 0.180 |
Why?
| | Substance Withdrawal Syndrome | 1 | 2023 | 184 | 0.180 |
Why?
| | Sinus Thrombosis, Intracranial | 1 | 2021 | 22 | 0.180 |
Why?
| | Narcotic Antagonists | 2 | 2020 | 186 | 0.170 |
Why?
| | Research Design | 3 | 2006 | 1120 | 0.170 |
Why?
| | Fractures, Bone | 2 | 2017 | 397 | 0.170 |
Why?
| | Hyperthermia, Induced | 1 | 2022 | 120 | 0.170 |
Why?
| | Opiate Substitution Treatment | 2 | 2020 | 156 | 0.170 |
Why?
| | Heart Atria | 1 | 2001 | 137 | 0.170 |
Why?
| | Acute Disease | 2 | 2019 | 993 | 0.170 |
Why?
| | Myocardial Contraction | 1 | 2001 | 303 | 0.160 |
Why?
| | Immunoglobulin Fragments | 1 | 1999 | 12 | 0.160 |
Why?
| | Droperidol | 1 | 1999 | 5 | 0.160 |
Why?
| | Lysergic Acid Diethylamide | 1 | 1999 | 3 | 0.160 |
Why?
| | Lithium Carbonate | 1 | 1999 | 6 | 0.160 |
Why?
| | Serotonin Syndrome | 1 | 1999 | 4 | 0.160 |
Why?
| | Wisconsin | 1 | 2020 | 101 | 0.160 |
Why?
| | Serotonin Receptor Agonists | 1 | 1999 | 26 | 0.160 |
Why?
| | Starch | 1 | 2019 | 22 | 0.160 |
Why?
| | Scorpion Stings | 1 | 1999 | 1 | 0.160 |
Why?
| | Survival Analysis | 4 | 2010 | 1311 | 0.160 |
Why?
| | Nutritive Value | 1 | 2019 | 37 | 0.160 |
Why?
| | Healthy Volunteers | 2 | 2019 | 208 | 0.150 |
Why?
| | Geriatric Assessment | 2 | 2011 | 219 | 0.150 |
Why?
| | Ventricular Premature Complexes | 1 | 1999 | 36 | 0.150 |
Why?
| | Snake Bites | 1 | 1999 | 23 | 0.150 |
Why?
| | Administration, Oral | 4 | 2019 | 787 | 0.150 |
Why?
| | Thrombocytopenia | 1 | 2021 | 205 | 0.150 |
Why?
| | Community Health Workers | 1 | 2020 | 62 | 0.150 |
Why?
| | Immune System | 1 | 2020 | 181 | 0.150 |
Why?
| | Fallopian Tube Diseases | 1 | 1998 | 4 | 0.150 |
Why?
| | Pregnancy, Tubal | 1 | 1998 | 5 | 0.150 |
Why?
| | Metabolome | 1 | 2022 | 352 | 0.150 |
Why?
| | Abortifacient Agents, Nonsteroidal | 1 | 1998 | 20 | 0.150 |
Why?
| | Munchausen Syndrome by Proxy | 1 | 1998 | 2 | 0.150 |
Why?
| | Dietary Carbohydrates | 1 | 2019 | 154 | 0.150 |
Why?
| | Drug Therapy, Combination | 4 | 2011 | 1031 | 0.150 |
Why?
| | Mass Screening | 1 | 2007 | 1296 | 0.140 |
Why?
| | Cohort Studies | 7 | 2023 | 5744 | 0.140 |
Why?
| | Plant Extracts | 1 | 2020 | 209 | 0.140 |
Why?
| | Chi-Square Distribution | 2 | 2017 | 522 | 0.140 |
Why?
| | Anticonvulsants | 1 | 2020 | 219 | 0.140 |
Why?
| | Cannabidiol | 1 | 2020 | 123 | 0.140 |
Why?
| | Sex Factors | 5 | 2022 | 2050 | 0.140 |
Why?
| | Sulfasalazine | 1 | 1998 | 23 | 0.140 |
Why?
| | Drug Antagonism | 2 | 2009 | 10 | 0.140 |
Why?
| | Faculty, Medical | 1 | 2021 | 290 | 0.140 |
Why?
| | Genome-Wide Association Study | 2 | 2023 | 1391 | 0.140 |
Why?
| | Dietary Fats | 1 | 2019 | 301 | 0.140 |
Why?
| | Drug Interactions | 4 | 2014 | 404 | 0.140 |
Why?
| | Dyspnea | 1 | 1999 | 254 | 0.130 |
Why?
| | Peptide Fragments | 1 | 2021 | 694 | 0.130 |
Why?
| | Methotrexate | 1 | 1998 | 255 | 0.130 |
Why?
| | Continuity of Patient Care | 1 | 2020 | 283 | 0.130 |
Why?
| | Gastrointestinal Agents | 1 | 1998 | 65 | 0.130 |
Why?
| | Fellowships and Scholarships | 1 | 2021 | 310 | 0.130 |
Why?
| | Survival Rate | 3 | 2013 | 1934 | 0.130 |
Why?
| | Out-of-Hospital Cardiac Arrest | 1 | 2018 | 120 | 0.130 |
Why?
| | Mice | 8 | 2009 | 17828 | 0.130 |
Why?
| | Incidence | 4 | 2013 | 2830 | 0.130 |
Why?
| | Ammonium Compounds | 1 | 2016 | 3 | 0.130 |
Why?
| | Simulation Training | 1 | 2018 | 110 | 0.130 |
Why?
| | Energy Intake | 1 | 2019 | 506 | 0.130 |
Why?
| | Clinical Trials as Topic | 2 | 2012 | 1034 | 0.120 |
Why?
| | Cytochrome P-450 CYP2E1 Inhibitors | 1 | 2016 | 2 | 0.120 |
Why?
| | Metabolic Clearance Rate | 2 | 2019 | 116 | 0.120 |
Why?
| | Ventricular Fibrillation | 1 | 2016 | 60 | 0.120 |
Why?
| | Prenatal Care | 1 | 2019 | 299 | 0.120 |
Why?
| | Half-Life | 2 | 2019 | 146 | 0.120 |
Why?
| | Hypnotics and Sedatives | 1 | 1998 | 211 | 0.120 |
Why?
| | Pain Management | 2 | 2017 | 389 | 0.120 |
Why?
| | Pharmacovigilance | 1 | 2015 | 23 | 0.120 |
Why?
| | Predictive Value of Tests | 3 | 2015 | 2030 | 0.120 |
Why?
| | Milk | 1 | 2016 | 123 | 0.120 |
Why?
| | Herniorrhaphy | 1 | 2016 | 70 | 0.120 |
Why?
| | Genetic Variation | 1 | 2020 | 990 | 0.120 |
Why?
| | Fatal Outcome | 2 | 2013 | 309 | 0.120 |
Why?
| | Adverse Drug Reaction Reporting Systems | 1 | 2015 | 77 | 0.110 |
Why?
| | Pilot Projects | 1 | 2020 | 1765 | 0.110 |
Why?
| | Hemodialysis Units, Hospital | 1 | 1994 | 5 | 0.110 |
Why?
| | Models, Biological | 2 | 2015 | 1810 | 0.110 |
Why?
| | Child Behavior | 1 | 2017 | 249 | 0.110 |
Why?
| | Ondansetron | 1 | 2014 | 18 | 0.110 |
Why?
| | Liver Failure, Acute | 1 | 2015 | 64 | 0.110 |
Why?
| | Patient Simulation | 1 | 2014 | 36 | 0.110 |
Why?
| | Total Quality Management | 1 | 1994 | 61 | 0.110 |
Why?
| | Cytochrome P-450 CYP2D6 | 1 | 2014 | 31 | 0.110 |
Why?
| | Hydrocodone | 1 | 2014 | 18 | 0.110 |
Why?
| | Personnel Staffing and Scheduling | 1 | 2015 | 97 | 0.110 |
Why?
| | Transaminases | 1 | 2014 | 23 | 0.110 |
Why?
| | Oxycodone | 1 | 2014 | 48 | 0.110 |
Why?
| | Curriculum | 1 | 2021 | 1008 | 0.110 |
Why?
| | Internship and Residency | 2 | 2014 | 1183 | 0.110 |
Why?
| | Guanfacine | 1 | 2013 | 5 | 0.100 |
Why?
| | Physicians | 2 | 2020 | 930 | 0.100 |
Why?
| | Clonidine | 1 | 2013 | 34 | 0.100 |
Why?
| | Prognosis | 3 | 2011 | 3995 | 0.100 |
Why?
| | Remote Consultation | 1 | 2014 | 58 | 0.100 |
Why?
| | International Normalized Ratio | 2 | 2011 | 47 | 0.100 |
Why?
| | Pregnancy Complications | 1 | 2019 | 538 | 0.100 |
Why?
| | Acute Pain | 1 | 2014 | 51 | 0.100 |
Why?
| | Vitamins | 1 | 2015 | 188 | 0.100 |
Why?
| | Cesium | 1 | 2013 | 20 | 0.100 |
Why?
| | Indazoles | 1 | 2014 | 67 | 0.100 |
Why?
| | Food | 1 | 2015 | 165 | 0.100 |
Why?
| | Deoxycholic Acid | 1 | 2013 | 17 | 0.100 |
Why?
| | Lethargy | 1 | 2012 | 4 | 0.100 |
Why?
| | Duloxetine Hydrochloride | 1 | 2012 | 13 | 0.100 |
Why?
| | Canada | 2 | 2025 | 408 | 0.100 |
Why?
| | Dabigatran | 1 | 2012 | 23 | 0.100 |
Why?
| | Pain Measurement | 4 | 2019 | 549 | 0.100 |
Why?
| | Walking | 1 | 2017 | 541 | 0.100 |
Why?
| | Sleep Stages | 1 | 2012 | 50 | 0.100 |
Why?
| | Tachycardia | 1 | 2012 | 55 | 0.100 |
Why?
| | Chlorides | 1 | 2013 | 138 | 0.100 |
Why?
| | Pyrazoles | 1 | 2016 | 425 | 0.100 |
Why?
| | Sulfhydryl Reagents | 1 | 2012 | 12 | 0.090 |
Why?
| | Attitude of Health Personnel | 1 | 2020 | 1159 | 0.090 |
Why?
| | Marijuana Abuse | 1 | 2015 | 226 | 0.090 |
Why?
| | Data Collection | 2 | 2013 | 660 | 0.090 |
Why?
| | Mycoses | 1 | 2013 | 82 | 0.090 |
Why?
| | Dizziness | 1 | 2012 | 81 | 0.090 |
Why?
| | Sampling Studies | 1 | 2012 | 101 | 0.090 |
Why?
| | Arsenicals | 1 | 2012 | 30 | 0.090 |
Why?
| | Athletic Performance | 1 | 2013 | 79 | 0.090 |
Why?
| | Magnesium | 2 | 2004 | 158 | 0.090 |
Why?
| | Patient Discharge | 2 | 2016 | 915 | 0.090 |
Why?
| | Drug Combinations | 1 | 2013 | 346 | 0.090 |
Why?
| | Accidental Falls | 2 | 2011 | 193 | 0.090 |
Why?
| | Information Systems | 1 | 2011 | 61 | 0.090 |
Why?
| | Sulfides | 1 | 2012 | 82 | 0.090 |
Why?
| | Laparoscopy | 1 | 2016 | 452 | 0.090 |
Why?
| | Follow-Up Studies | 3 | 2010 | 5152 | 0.090 |
Why?
| | Arabia | 1 | 2011 | 2 | 0.090 |
Why?
| | Levamisole | 1 | 2011 | 19 | 0.090 |
Why?
| | Immunocompromised Host | 1 | 2013 | 201 | 0.090 |
Why?
| | Marijuana Smoking | 1 | 2015 | 261 | 0.090 |
Why?
| | Hepatic Encephalopathy | 1 | 2011 | 24 | 0.090 |
Why?
| | Structure-Activity Relationship | 1 | 2012 | 570 | 0.090 |
Why?
| | Drug Contamination | 1 | 2011 | 52 | 0.090 |
Why?
| | Molecular Structure | 1 | 2012 | 498 | 0.090 |
Why?
| | Dietary Supplements | 1 | 2015 | 559 | 0.080 |
Why?
| | Pharmacogenetics | 1 | 2012 | 164 | 0.080 |
Why?
| | Sports | 1 | 2013 | 217 | 0.080 |
Why?
| | Universities | 1 | 2013 | 434 | 0.080 |
Why?
| | Glipizide | 1 | 2010 | 6 | 0.080 |
Why?
| | Laboratories, Hospital | 1 | 2010 | 12 | 0.080 |
Why?
| | Hepatitis, Alcoholic | 1 | 2010 | 14 | 0.080 |
Why?
| | Troponin | 1 | 2010 | 51 | 0.080 |
Why?
| | Glyburide | 1 | 2010 | 32 | 0.080 |
Why?
| | Crowding | 1 | 2010 | 36 | 0.080 |
Why?
| | Drug Prescriptions | 2 | 2016 | 260 | 0.080 |
Why?
| | Biological Availability | 2 | 2019 | 137 | 0.080 |
Why?
| | Watchful Waiting | 1 | 2010 | 77 | 0.080 |
Why?
| | Body Weight | 1 | 2014 | 996 | 0.080 |
Why?
| | Adjuvants, Immunologic | 1 | 2011 | 237 | 0.080 |
Why?
| | Quetiapine Fumarate | 1 | 2009 | 24 | 0.080 |
Why?
| | Dibenzothiazepines | 1 | 2009 | 18 | 0.080 |
Why?
| | Aripiprazole | 1 | 2009 | 21 | 0.080 |
Why?
| | Risperidone | 1 | 2009 | 31 | 0.080 |
Why?
| | Potassium | 1 | 2009 | 147 | 0.080 |
Why?
| | Role | 1 | 2009 | 30 | 0.080 |
Why?
| | Efficiency, Organizational | 1 | 2010 | 139 | 0.070 |
Why?
| | Head Protective Devices | 1 | 2009 | 25 | 0.070 |
Why?
| | Dogs | 1 | 2010 | 425 | 0.070 |
Why?
| | Quality Control | 1 | 2009 | 173 | 0.070 |
Why?
| | Renal Dialysis | 1 | 2013 | 445 | 0.070 |
Why?
| | Acidosis | 2 | 2006 | 101 | 0.070 |
Why?
| | Glutathione | 3 | 2022 | 357 | 0.070 |
Why?
| | Bibliometrics | 1 | 2009 | 65 | 0.070 |
Why?
| | Verapamil | 2 | 2014 | 40 | 0.070 |
Why?
| | Diarrhea | 1 | 2009 | 182 | 0.070 |
Why?
| | Intensive Care Units, Pediatric | 1 | 2011 | 262 | 0.070 |
Why?
| | Body Temperature | 1 | 2009 | 223 | 0.070 |
Why?
| | Quality Indicators, Health Care | 1 | 2011 | 308 | 0.070 |
Why?
| | Workload | 1 | 2010 | 162 | 0.070 |
Why?
| | Skiing | 1 | 2009 | 50 | 0.070 |
Why?
| | Pharmacy Service, Hospital | 1 | 2009 | 87 | 0.070 |
Why?
| | Bacitracin | 1 | 2008 | 5 | 0.070 |
Why?
| | Adhesiveness | 1 | 2008 | 20 | 0.070 |
Why?
| | Acetone | 1 | 2008 | 12 | 0.070 |
Why?
| | Hair Preparations | 1 | 2008 | 7 | 0.070 |
Why?
| | Propylene Glycols | 1 | 2008 | 27 | 0.070 |
Why?
| | Informed Consent | 2 | 2006 | 188 | 0.070 |
Why?
| | Nylons | 1 | 2008 | 20 | 0.070 |
Why?
| | Equipment Design | 1 | 2009 | 518 | 0.070 |
Why?
| | Health Services Accessibility | 1 | 2015 | 993 | 0.070 |
Why?
| | Cause of Death | 1 | 2010 | 433 | 0.070 |
Why?
| | Withholding Treatment | 1 | 2008 | 77 | 0.070 |
Why?
| | Students | 1 | 2013 | 627 | 0.070 |
Why?
| | Glycerol | 1 | 2008 | 91 | 0.070 |
Why?
| | Cellulose | 1 | 2008 | 60 | 0.070 |
Why?
| | Quinolones | 1 | 2009 | 135 | 0.070 |
Why?
| | Drug Synergism | 1 | 2008 | 367 | 0.070 |
Why?
| | Military Personnel | 1 | 2014 | 608 | 0.070 |
Why?
| | Nephelometry and Turbidimetry | 1 | 2007 | 15 | 0.070 |
Why?
| | Laboratories | 1 | 2008 | 107 | 0.070 |
Why?
| | Substance Abuse Detection | 2 | 2021 | 101 | 0.070 |
Why?
| | Polypharmacy | 1 | 2008 | 88 | 0.070 |
Why?
| | Tissue Distribution | 2 | 2019 | 330 | 0.060 |
Why?
| | Phosphates | 1 | 2008 | 180 | 0.060 |
Why?
| | Formates | 1 | 2006 | 14 | 0.060 |
Why?
| | Research | 2 | 2011 | 451 | 0.060 |
Why?
| | Defibrillators | 1 | 2006 | 21 | 0.060 |
Why?
| | Kidney Transplantation | 1 | 2013 | 658 | 0.060 |
Why?
| | Combined Modality Therapy | 1 | 2009 | 1235 | 0.060 |
Why?
| | Periodicals as Topic | 1 | 2009 | 211 | 0.060 |
Why?
| | Methanol | 1 | 2006 | 43 | 0.060 |
Why?
| | Vasopressins | 1 | 2006 | 60 | 0.060 |
Why?
| | Statistics, Nonparametric | 1 | 2007 | 433 | 0.060 |
Why?
| | Blindness | 1 | 2006 | 48 | 0.060 |
Why?
| | Probability | 2 | 2010 | 308 | 0.060 |
Why?
| | Spinal Diseases | 1 | 2006 | 51 | 0.060 |
Why?
| | Health Services for the Aged | 1 | 2006 | 72 | 0.060 |
Why?
| | Naproxen | 1 | 2006 | 17 | 0.060 |
Why?
| | Ipecac | 1 | 2005 | 8 | 0.060 |
Why?
| | Hospitalization | 2 | 2011 | 2228 | 0.060 |
Why?
| | Epinephrine | 1 | 2006 | 145 | 0.060 |
Why?
| | Aging | 2 | 2014 | 1857 | 0.060 |
Why?
| | Respiratory Insufficiency | 1 | 2009 | 326 | 0.060 |
Why?
| | Population Dynamics | 1 | 2006 | 148 | 0.060 |
Why?
| | Ibuprofen | 1 | 2006 | 82 | 0.060 |
Why?
| | Hospitals, University | 1 | 2006 | 175 | 0.060 |
Why?
| | Haplorhini | 1 | 2005 | 53 | 0.060 |
Why?
| | Telemedicine | 1 | 2014 | 876 | 0.060 |
Why?
| | Premedication | 1 | 2005 | 41 | 0.060 |
Why?
| | Geriatrics | 1 | 2006 | 91 | 0.060 |
Why?
| | Practice Guidelines as Topic | 2 | 2014 | 1569 | 0.060 |
Why?
| | Respiration, Artificial | 1 | 2009 | 670 | 0.060 |
Why?
| | Risk | 1 | 2007 | 913 | 0.060 |
Why?
| | Spine | 1 | 2006 | 179 | 0.050 |
Why?
| | Single-Blind Method | 1 | 2005 | 286 | 0.050 |
Why?
| | Water | 1 | 2008 | 461 | 0.050 |
Why?
| | Fluoride Poisoning | 1 | 2004 | 3 | 0.050 |
Why?
| | Phenobarbital | 1 | 2023 | 18 | 0.050 |
Why?
| | Motivation | 1 | 2009 | 592 | 0.050 |
Why?
| | Blood Glucose | 2 | 2019 | 2241 | 0.050 |
Why?
| | Resuscitation | 1 | 2006 | 275 | 0.050 |
Why?
| | Guidelines as Topic | 1 | 2005 | 272 | 0.050 |
Why?
| | Hydroxyzine | 1 | 2023 | 4 | 0.050 |
Why?
| | Maltose | 1 | 2023 | 8 | 0.050 |
Why?
| | Delphi Technique | 1 | 2025 | 290 | 0.050 |
Why?
| | Health Policy | 1 | 2006 | 398 | 0.050 |
Why?
| | Mycophenolic Acid | 1 | 2004 | 117 | 0.050 |
Why?
| | Sheep | 1 | 2006 | 864 | 0.050 |
Why?
| | Urea | 1 | 2023 | 79 | 0.050 |
Why?
| | Survival | 1 | 2003 | 39 | 0.050 |
Why?
| | Aspirin | 1 | 2006 | 390 | 0.050 |
Why?
| | Pregnancy | 3 | 2021 | 6870 | 0.050 |
Why?
| | Patient Participation | 1 | 2006 | 428 | 0.050 |
Why?
| | Internet | 1 | 2007 | 674 | 0.050 |
Why?
| | Lactates | 1 | 2022 | 85 | 0.050 |
Why?
| | Sex Distribution | 2 | 2015 | 380 | 0.050 |
Why?
| | Culture Techniques | 1 | 2001 | 74 | 0.050 |
Why?
| | Urban Population | 2 | 2019 | 485 | 0.050 |
Why?
| | Prevalence | 3 | 2015 | 2745 | 0.050 |
Why?
| | Blood Physiological Phenomena | 1 | 2021 | 13 | 0.040 |
Why?
| | Consensus | 1 | 2025 | 683 | 0.040 |
Why?
| | Neural Conduction | 1 | 2001 | 89 | 0.040 |
Why?
| | Academic Medical Centers | 2 | 2016 | 513 | 0.040 |
Why?
| | Hirudins | 1 | 2021 | 52 | 0.040 |
Why?
| | Breast Neoplasms | 1 | 2013 | 2283 | 0.040 |
Why?
| | Calcium Channel Blockers | 1 | 2001 | 172 | 0.040 |
Why?
| | Controlled Clinical Trials as Topic | 1 | 2020 | 28 | 0.040 |
Why?
| | Infusions, Parenteral | 1 | 2020 | 43 | 0.040 |
Why?
| | Pirenzepine | 1 | 1999 | 8 | 0.040 |
Why?
| | Scorpions | 1 | 1999 | 3 | 0.040 |
Why?
| | South America | 1 | 1999 | 59 | 0.040 |
Why?
| | Certification | 1 | 2020 | 117 | 0.040 |
Why?
| | Blood Cell Count | 2 | 2013 | 54 | 0.040 |
Why?
| | Temperature | 1 | 2022 | 660 | 0.040 |
Why?
| | Narcotics | 1 | 1999 | 55 | 0.040 |
Why?
| | Rupture, Spontaneous | 1 | 1998 | 15 | 0.040 |
Why?
| | Postprandial Period | 1 | 2019 | 110 | 0.040 |
Why?
| | Central Nervous System Depressants | 1 | 1999 | 86 | 0.040 |
Why?
| | Immunosuppressive Agents | 1 | 2004 | 848 | 0.040 |
Why?
| | Ambulatory Care | 1 | 2023 | 575 | 0.040 |
Why?
| | Videotape Recording | 1 | 2018 | 39 | 0.040 |
Why?
| | Manikins | 1 | 2018 | 35 | 0.040 |
Why?
| | Analysis of Variance | 1 | 2001 | 1317 | 0.040 |
Why?
| | Sorption Detoxification | 1 | 1998 | 2 | 0.040 |
Why?
| | Dietary Proteins | 1 | 2019 | 135 | 0.040 |
Why?
| | North America | 1 | 1999 | 304 | 0.040 |
Why?
| | Cholinesterase Inhibitors | 1 | 1998 | 38 | 0.040 |
Why?
| | Laparotomy | 1 | 1998 | 112 | 0.040 |
Why?
| | Feedback | 1 | 2018 | 174 | 0.030 |
Why?
| | Recombinant Proteins | 1 | 2021 | 1355 | 0.030 |
Why?
| | Cardiomyopathies | 1 | 2001 | 325 | 0.030 |
Why?
| | Lipids | 1 | 2022 | 675 | 0.030 |
Why?
| | Central Nervous System | 1 | 1999 | 264 | 0.030 |
Why?
| | Cross-Over Studies | 1 | 2019 | 555 | 0.030 |
Why?
| | Triglycerides | 1 | 2019 | 513 | 0.030 |
Why?
| | Maternal Health Services | 1 | 2019 | 101 | 0.030 |
Why?
| | Immunoglobulin G | 1 | 2001 | 898 | 0.030 |
Why?
| | Socioeconomic Factors | 2 | 2015 | 1312 | 0.030 |
Why?
| | Registries | 2 | 2010 | 2081 | 0.030 |
Why?
| | Bipolar Disorder | 1 | 1999 | 273 | 0.030 |
Why?
| | Oxidation-Reduction | 1 | 2019 | 1076 | 0.030 |
Why?
| | Dialysis | 1 | 2015 | 18 | 0.030 |
Why?
| | Hallucinogens | 1 | 2017 | 110 | 0.030 |
Why?
| | Centrifugation | 1 | 2015 | 27 | 0.030 |
Why?
| | Tennessee | 1 | 1994 | 50 | 0.030 |
Why?
| | Observation | 1 | 2014 | 57 | 0.030 |
Why?
| | Hematocrit | 1 | 1994 | 103 | 0.030 |
Why?
| | Program Evaluation | 1 | 2018 | 917 | 0.030 |
Why?
| | International Classification of Diseases | 1 | 2015 | 138 | 0.030 |
Why?
| | Syndrome | 1 | 2015 | 377 | 0.030 |
Why?
| | Anesthetics, Local | 1 | 2014 | 98 | 0.030 |
Why?
| | Warfare | 1 | 2014 | 83 | 0.030 |
Why?
| | Erythropoietin | 1 | 1994 | 97 | 0.030 |
Why?
| | Injections, Intralesional | 1 | 2013 | 35 | 0.030 |
Why?
| | Protein Binding | 1 | 2020 | 2233 | 0.030 |
Why?
| | Hospitals, Veterans | 1 | 1994 | 255 | 0.030 |
Why?
| | Salicylates | 1 | 2013 | 29 | 0.020 |
Why?
| | Urinalysis | 1 | 2013 | 77 | 0.020 |
Why?
| | Long QT Syndrome | 1 | 2013 | 67 | 0.020 |
Why?
| | Nursing Staff, Hospital | 1 | 1994 | 158 | 0.020 |
Why?
| | Hemoglobins | 1 | 1994 | 357 | 0.020 |
Why?
| | Iron | 1 | 1994 | 324 | 0.020 |
Why?
| | Therapeutic Irrigation | 1 | 2012 | 79 | 0.020 |
Why?
| | Receptors, Opioid, mu | 1 | 2012 | 70 | 0.020 |
Why?
| | Agranulocytosis | 1 | 2011 | 32 | 0.020 |
Why?
| | Vasculitis, Leukocytoclastic, Cutaneous | 1 | 2011 | 8 | 0.020 |
Why?
| | False Negative Reactions | 1 | 2011 | 60 | 0.020 |
Why?
| | Cytochrome P-450 Enzyme System | 1 | 2012 | 158 | 0.020 |
Why?
| | Leukoencephalopathies | 1 | 2011 | 19 | 0.020 |
Why?
| | Computer Simulation | 1 | 2015 | 995 | 0.020 |
Why?
| | Fluid Therapy | 1 | 2012 | 137 | 0.020 |
Why?
| | Insulin Resistance | 1 | 2019 | 1222 | 0.020 |
Why?
| | Gas Chromatography-Mass Spectrometry | 1 | 2011 | 135 | 0.020 |
Why?
| | Toothache | 1 | 2010 | 5 | 0.020 |
Why?
| | Models, Theoretical | 1 | 1994 | 581 | 0.020 |
Why?
| | Immunoassay | 1 | 2011 | 111 | 0.020 |
Why?
| | Quality of Health Care | 1 | 2015 | 657 | 0.020 |
Why?
| | Drug Administration Routes | 1 | 2010 | 41 | 0.020 |
Why?
| | Disease Outbreaks | 1 | 2014 | 416 | 0.020 |
Why?
| | Insurance Coverage | 1 | 2012 | 235 | 0.020 |
Why?
| | Injections, Intravenous | 1 | 2010 | 202 | 0.020 |
Why?
| | Neurologic Examination | 1 | 2010 | 128 | 0.020 |
Why?
| | Patient Education as Topic | 1 | 1994 | 766 | 0.020 |
Why?
| | Age Distribution | 1 | 2010 | 401 | 0.020 |
Why?
| | Polymorphism, Genetic | 1 | 2012 | 624 | 0.020 |
Why?
| | Intestines | 1 | 2012 | 356 | 0.020 |
Why?
| | Kidney Failure, Chronic | 1 | 1994 | 575 | 0.020 |
Why?
| | Safety | 1 | 2010 | 348 | 0.020 |
Why?
| | Precision Medicine | 1 | 2012 | 421 | 0.020 |
Why?
| | Ethanol | 1 | 2012 | 615 | 0.020 |
Why?
| | Regression Analysis | 1 | 2010 | 1021 | 0.020 |
Why?
| | Seasons | 1 | 2010 | 538 | 0.020 |
Why?
| | Disease Management | 1 | 2011 | 621 | 0.020 |
Why?
| | Bilirubin | 1 | 2007 | 89 | 0.020 |
Why?
| | Pulse | 1 | 2006 | 26 | 0.020 |
Why?
| | Genotype | 1 | 2012 | 1849 | 0.020 |
Why?
| | Clinical Competence | 1 | 2014 | 1149 | 0.020 |
Why?
| | Blastomycosis | 1 | 2006 | 11 | 0.020 |
Why?
| | Metabolomics | 1 | 2012 | 689 | 0.020 |
Why?
| | Contraindications | 1 | 2006 | 86 | 0.020 |
Why?
| | Biopsy, Fine-Needle | 1 | 2006 | 70 | 0.020 |
Why?
| | Amyloidosis | 1 | 2006 | 48 | 0.020 |
Why?
| | Coronary Circulation | 1 | 2006 | 136 | 0.020 |
Why?
| | Electric Countershock | 1 | 2006 | 106 | 0.020 |
Why?
| | European Union | 1 | 2005 | 12 | 0.020 |
Why?
| | Fever | 1 | 2007 | 305 | 0.010 |
Why?
| | Disaster Planning | 1 | 2006 | 97 | 0.010 |
Why?
| | Emergencies | 1 | 2006 | 178 | 0.010 |
Why?
| | Infant, Newborn | 2 | 2007 | 6158 | 0.010 |
Why?
| | Administration, Inhalation | 1 | 2006 | 595 | 0.010 |
Why?
| | United States Food and Drug Administration | 1 | 2005 | 205 | 0.010 |
Why?
| | Up-Regulation | 1 | 2007 | 852 | 0.010 |
Why?
| | Pharmaceutical Preparations | 1 | 2006 | 176 | 0.010 |
Why?
| | Renal Insufficiency | 1 | 2006 | 162 | 0.010 |
Why?
| | Swine | 1 | 2006 | 800 | 0.010 |
Why?
| | Mice, Inbred ICR | 1 | 2004 | 119 | 0.010 |
Why?
| | Brain Injuries | 1 | 2009 | 500 | 0.010 |
Why?
| | Lupus Nephritis | 1 | 2004 | 65 | 0.010 |
Why?
| | Phenotype | 1 | 2012 | 3143 | 0.010 |
Why?
| | In Vitro Techniques | 1 | 2004 | 1090 | 0.010 |
Why?
| | Papillary Muscles | 1 | 2001 | 13 | 0.010 |
Why?
| | Models, Cardiovascular | 1 | 2001 | 197 | 0.010 |
Why?
| | Blood Pressure | 1 | 2006 | 1737 | 0.010 |
Why?
| | Miosis | 1 | 1999 | 4 | 0.010 |
Why?
| | Pupil | 1 | 1999 | 22 | 0.010 |
Why?
| | Hemodynamics | 1 | 2004 | 1093 | 0.010 |
Why?
| | Chronic Disease | 1 | 2004 | 1804 | 0.010 |
Why?
| | Algorithms | 1 | 2004 | 1730 | 0.010 |
Why?
| | Rats, Sprague-Dawley | 1 | 2001 | 2497 | 0.010 |
Why?
| | Rats | 1 | 2001 | 5591 | 0.010 |
Why?
| | Neoplasms | 1 | 2006 | 2687 | 0.010 |
Why?
|
|
Heard's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|